Literature DB >> 22152184

Social valuation of EQ-5D health states: the Chilean case.

Victor Zarate1, Paul Kind, Paulina Valenzuela, Alberto Vignau, Pedro Olivares-Tirado, Alberto Munoz.   

Abstract

BACKGROUND: Cost-effectiveness analysis has been recommended by many national agencies around the world as a valid methodology to improve resource allocation within the health-care system. If the preferences of the society are taken into account in such a decision-making process, it is generally recommended that these values should be elicited by using a generic health-related quality-of-life instrument, such as the EuroQol five-dimensional (EQ-5D) questionnaire.
OBJECTIVES: To estimate a set of social values for EQ-5D questionnaire based on the time trade-off valuation technique for use in Chile.
METHODS: A valuation questionnaire was applied to a probabilistic sample of 2000 individuals, aged 20 years or older, living in the Metropolitan region. The fieldwork took place during October to November 2008. Utility weights for 42 health states were calculated directly by the application of time trade-off. Several random effect and ordinary least-squares regression models were fitted to these valuations to predict the full set of 243 health states generated by the EQ-5D system. The best model was chosen by applying criteria of parsimony, goodness of fit, and prediction capacity.
RESULTS: The selected regression model was robust and showed better predictive characteristics than others reported in similar studies conducted elsewhere. The chosen regression model showed a R(2) of 0.34, mean absolute error of 0.017, and high predictive capacity.
CONCLUSIONS: This study provides an EQ-5D social value set for domestic use in Chile. Our results differ from those reported in other countries, justifying the need to perform local studies that adequately reflect societal health preferences.
Copyright © 2011 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22152184     DOI: 10.1016/j.jval.2011.09.002

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  17 in total

1.  An EQ-5D-5L value set based on Uruguayan population preferences.

Authors:  Federico Augustovski; Lucila Rey-Ares; Vilma Irazola; Osvaldo Ulises Garay; Oscar Gianneo; Graciela Fernández; Marcelo Morales; Luz Gibbons; Juan Manuel Ramos-Goñi
Journal:  Qual Life Res       Date:  2015-08-05       Impact factor: 4.147

2.  Chilean population norms derived from the health-related quality of Life SF-6D.

Authors:  Miguel A Garcia-Gordillo; Daniel Collado-Mateo; Pedro R Olivares; José C Adsuar
Journal:  Eur J Health Econ       Date:  2017-06-19

3.  Valuation of EQ-5D-3L health states in Singapore: modeling of time trade-off values for 80 empirically observed health states.

Authors:  Nan Luo; Pei Wang; Julian Thumboo; Yee-Wei Lim; Hubertus J M Vrijhoef
Journal:  Pharmacoeconomics       Date:  2014-05       Impact factor: 4.981

Review 4.  Between-country heterogeneity in EQ-5D-3L scoring algorithms: how much is due to differences in health state selection?

Authors:  Eleanor M Pullenayegum; Kuhan Perampaladas; Kathryn Gaebel; Brett Doble; Feng Xie
Journal:  Eur J Health Econ       Date:  2014-09-25

5.  Prevalence, burden of disease, and lost in health state utilities attributable to chronic musculoskeletal disorders and pain in Chile.

Authors:  Pedro Zitko; Norberto Bilbeny; Carlos Balmaceda; Tomas Abbott; Cesar Carcamo; Manuel Espinoza
Journal:  BMC Public Health       Date:  2021-05-17       Impact factor: 3.295

6.  Study protocol for valuing EQ-5D-3L and EORTC-8D health states in a representative population sample in Sri Lanka.

Authors:  Sanjeewa Kularatna; Jennifer A Whitty; Newell W Johnson; Paul A Scuffham
Journal:  Health Qual Life Outcomes       Date:  2013-09-02       Impact factor: 3.186

Review 7.  Is Health Related Quality of Life (HRQoL) a valid indicator for health systems evaluation?

Authors:  Martin Romero; David Vivas-Consuelo; Nelson Alvis-Guzman
Journal:  Springerplus       Date:  2013-12-11

8.  Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Naïve Patients in Chile.

Authors:  Constanza L Vargas; Manuel A Espinoza; Andrés Giglio; Alejandro Soza
Journal:  PLoS One       Date:  2015-11-06       Impact factor: 3.240

9.  Measuring the Benefits of Healthcare: DALYs and QALYs - Does the Choice of Measure Matter? A Case Study of Two Preventive Interventions.

Authors:  Andres Pichon-Riviere; Federico Augustovski; Lisandro D Colantonio; Julieta Galante; Ariel Bardach; Joaquín E Caporale; Víctor Zárate; Ling Hsiang Chuang; Paul Kind
Journal:  Int J Health Policy Manag       Date:  2018-02-01

10.  Differences in utility scores obtained through Brazilian and UK value sets: a cross-sectional study.

Authors:  Maíra Libertad Soligo Takemoto; Nilceia Lopes da Silva; Ana Carolina Padula Ribeiro-Pereira; Arthur Orlando Correa Schilithz; Cibele Suzuki
Journal:  Health Qual Life Outcomes       Date:  2015-08-06       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.